Neomorph, a San Diego biotech player, has treated its first patient in a first-in-human trial of NEO‑811, an experimental "molecular glue" meant to trigger the destruction of a protein that fuels clear-cell kidney cancer. The move pushes the company’s lead program into the clinic and follows a string of multibillion-dollar tie-ups with major pharmaceutical partners.
Yesterday, Neomorph said it had started dosing in the Phase 1/2 NEO‑811‑101 study, an open-label, dose-escalation trial that will assess safety and tolerability, as well as early signs of anti-tumor activity, in people with locally advanced or metastatic clear-cell renal cell carcinoma. The study is listed on ClinicalTrials.gov as NCT07300241 and is expected to enroll roughly 30 participants across dose-finding and expansion cohorts. According to the company, Neomorph was founded in 2020 and is backed by Deerfield Management Company, which the company noted in its press release announcing the first-patient dosing milestone.
Big pharma has already taken notice. Neomorph has disclosed option-to-license and research collaborations structured so that AbbVie could pay up to $1.64 billion, Biogen about $1.45 billion, and Novo Nordisk roughly $1.46 billion, deals that together approach $4.6 billion. Announced over the past two years, these agreements highlight why established drugmakers are racing to secure positions in targeted-degradation platforms.
How molecular glue works
Instead of simply blocking a protein the way a traditional drug would, molecular glues coax the cell’s own trash-disposal system into getting rid of it. These small molecules stabilize or induce an interaction between an E3 ubiquitin ligase and a disease-driving protein, tagging the target with ubiquitin and handing it off to the proteasome for degradation, a mechanism described in technical reviews of targeted protein degradation. That ability to eliminate a difficult target, rather than just inhibit it, is what makes glues especially attractive in cancers and other diseases where standard inhibitors have not done the job.
Why the money is flowing
Industry watchers tend to point to two practical advantages. First, glue molecules are often smaller and more drug-like than bifunctional degraders, which can help with oral bioavailability and formulation. Second, they open a potential path to go after proteins that were long written off as undruggable. Academic and industry analyses have laid out these upsides and why companies are willing to pay a premium to secure access to the technology.
San Diego stake and patient impact
Kidney cancer remains a major clinical challenge. The American Cancer Society estimates there are roughly 80,000 new U.S. cases of kidney and renal pelvis cancer every year and notes that most patients are diagnosed between the ages of 55 and 74. That national burden helps explain the strong interest in fresh, targeted strategies for clear-cell disease, including in San Diego.
Local coverage by The San Diego Union‑Tribune, citing the California Cancer Registry, reports that about 500 San Diego County residents are diagnosed with kidney cancer each year. The paper also quoted Neomorph’s CEO as saying the company expects early clinical readouts from the NEO‑811 trial within about a year. The trial registry lists a primary completion date in January 2027, so initial safety findings and any hint of tumor responses from the dose-escalation phase will be the near-term milestones to watch.
If NEO‑811 delivers a clean safety profile and early activity, partners and investors are likely to move faster on development plans or exercise licensing options. If the results are less encouraging, timelines and partner strategies will adjust accordingly. For now, Neomorph’s step into the clinic marks a notable local moment for a new drug class that has already pulled billions of dollars into San Diego’s biotech ecosystem.
